TNGX SCHEDULE 13G/A: SEC filing

TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu

Filed with the SEC on · accession 0001193125-26-464026

TNGX filed a SCHEDULE 13G/A (schedule 13g/a) with the SEC on Nov 16, 2026. A report the company filed with the SEC (the US market regulator).

Summary of the filing

TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu filed an amended Schedule 13G reporting beneficial ownership of approximately 4.6% of Tango Therapeutics' common stock, including shares underlying pre-funded warrants.

Key details

Shares of common stock beneficially owned$7.8M
Percent of class beneficially owned$5
Reporting entity / beneficial ownerTCG Crossover Fund II, L.P.
General partner of tcg crossover fund ii, l.p.TCG Crossover GP II, LLC
IssuerTango Therapeutics, Inc.
Sole managing member of tcg crossover gp ii, llcChen Yu

✦ Ask GOAX AI about this filing — what it means for TNGX, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for TNGX?

Click here

Frequently asked questions

What did TNGX file with the SEC on Nov 16, 2026?

TNGX filed a SCHEDULE 13G/A (SEC filing). TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu filed an amended Schedule 13G reporting beneficial ownership of approximately 4.6% of Tango Therapeutics' common stock, including shares underlying pre-funded warrants.

How do I read a SCHEDULE 13G/A?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G/A (schedule 13g/a): A report the company filed with the SEC (the US market regulator).

Other TNGX SEC filings

Get alerts when TNGX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days